Jade Biosciences Inc

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Jade Biosciences Inc
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Frequently asked questions
To buy Jade Biosciences Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Jade Biosciences Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Jade Biosciences Inc is JBIO:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Jade Biosciences Inc has its primary listing on NASDAQ (Small cap). You can trade Jade Biosciences Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Jade Biosciences Inc is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Jade Biosciences Inc as part of a broader investment portfolio.